Alcon is a world leading pure-play eye care company, operating in two highly attractive and structurally growing markets: Ophthalmic Surgery and Vision Care. Supported by several structural growth drivers, these markets are expected to experience steady mid-single-digit growth. Alcon is projected to outperform this, driven by market share gains through product innovation. It enjoys high revenue recurrence (around 90%), a 2024-30e core EPS CAGR of 10.4%, strong free cash flow, and thus a solid ba...
GENEVA, Switzerland & ORLANDO, Fla.--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire LENSAR. The acquisition includes ALLY Robotic Cataract Laser Treatment System™, LENSAR’s proprietary Streamline® software technology and LENSAR legacy laser system, building Alcon’s femtosecond...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care, will host its 2025 Capital Markets Day on March 27, 2025, beginning at 8:00 a.m. CT. A live webcast of the event will be available at the following link: . Those wishing to participate should register and log on approximately 10 minutes before the start of the webcast. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care product...
TORONTO--(BUSINESS WIRE)-- Alcon (SIX/NYSE : ALC), le chef de file mondial en matière de soins oculaires qui se consacre à aider les gens à voir avec clarté, a annoncé aujourd’hui l’ajout de paramètres élargis à la gamme de lentilles TOTAL30MD pour l’astigmatisme, les premières et les seules lentilles cornéennes toriques à remplacement mensuel avec gradient d’eau1-3 qui procurent la même expérience de port exceptionnellement confortable5, maintenant offertes avec une puissance cylindrique de -2,75 D. Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : L...
TORONTO--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the availability of expanded parameters for TOTAL30® for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens,1-3 delivering the same exceptionally comfortable wearing experience,5 now in a –2.75D cylinder offering. This press release features multimedia. View the full release here: TOTAL30 for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens, is now available in expanded parameters. (...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2024. For the fourth quarter of 2024, sales were $2.5 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.57 and core diluted earnings per share2 of $0.72 in the fourth quarter of 2024. "In 2024, our unwavering focus on innovation and operational excellence delivered another set of strong results," said Dav...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of SYSTANE® PRO Preservative-Free (PF) as the latest over-the-counter eye drop in the company’s dry eye portfolio. SYSTANE PRO PF is the longest lasting eye drop in the SYSTANE portfolio with a unique triple action, preservative-free formula for the temporary relief of burning and irritation due to dryness of the eye.1 Dry eye disease is one of the most common ocular surface disorders, affecting an estimated 45.5 million people in the Uni...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care, dedicated to helping people see brilliantly, announced today the full U.S. commercial availability of Voyager™ DSLT, the first and only Direct Selective Laser Trabeculoplasty device (DSLT). Voyager DSLT is uniquely poised to accelerate the adoption of laser as a first-line therapy, unlocking the treatment’s availability for more patients. Designed for an exceptional patient and physician experience, Voyager DSLT is fully automated—efficiently delivering 120 laser pulses without the need for a gonio lens as with man...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2025 J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 p.m. PST. A live webcast of the conference will be available at . About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataract...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.